|Bid||89.35 x 1000|
|Ask||89.72 x 800|
|Day's Range||88.25 - 91.55|
|52 Week Range||37.01 - 95.95|
|Beta (5Y Monthly)||1.20|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb. 26, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||110.10|
Acceleron (XLRN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Acceleron Pharma Inc. (Nasdaq:XLRN) today announced it will host a webcast and conference call on Thursday, February 27, 2020 at 5:00 p.m. EST to discuss its fourth quarter and full year 2019 operating and financial results.
Investors will focus on regular top and bottom-line numbers along with key pipeline updates when Bristol-Myers (BMY) reports fourth-quarter results.
Acceleron (XLRN) stock surges as sotatercept meets primary and secondary endpoints in a phase II study in patients with pulmonary arterial hypertension.
Acceleron Pharma Inc. (NASDAQ:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta superfamily therapeutics to treat serious and rare diseases, today announced that the PULSAR Phase 2 trial of sotatercept met its primary and key secondary endpoints in patients with pulmonary arterial hypertension (PAH).
Acceleron Pharma Inc. (Nasdaq:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta superfamily therapeutics to treat serious and rare diseases, announced today that John Quisel, J.D., Ph.D, Executive Vice President and Chief Business Officer, is leaving the Company to become Chief Executive Officer of a venture-backed startup biotechnology company. Dr. Quisel’s departure from Acceleron is effective as of February 24.
New England Journal of Medicine Publishes Results of Pivotal Phase 3 Reblozyl® (luspatercept-aamt) MEDALIST Trial
Acceleron Pharma Inc. (Nasdaq:XLRN) today announced that senior management will participate at the 38th Annual J.P. Morgan Healthcare Conference in San Francisco, California.
One simple way to benefit from the stock market is to buy an index fund. But if you buy good businesses at attractive...
Acceleron (XLRN) signs a collaboration/license pact with Fulcrum Therapeutics aimed at identifying small molecules designed to modulate specific pathways targeting a pulmonary disease indication.
The FDA bestows a Breakthrough Therapy status on Agios' (AGIO) leukemia drug Tibsovo for treating relapsed/refractory myelodysplastic syndrome in adult patients with a susceptible IDH1 mutation.
Bristol-Myers (BMY) and Acceleron Pharma Inc.'s sBLA for Reblozyl in patients with myelodysplastic syndromes will be reviewed by the FDA's Oncologic Drugs Advisory Committee.
Geron's (GERN) telomerase inhibitor, imetelstat, is being evaluated in two clinical studies for patients with MDS and myelofibrosis. The candidate is progressing well in clinical studies.